Work

Alectinib as monotherapy for the first-line treatment of adult patients with ALK-positive advanced non-small cell lung cancer (NSCLC). EUnetHTA report

Year: 2018

Type: article

Authors: Dental, EUnetHTA Pharmaceutical Benefits Agency, Agency for Quality

Language: English

Topic: Lung Cancer Treatments and Mutations

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2784573490

FWCI:

Cites:

Cited by:

Related to: 10